Provided by Tiger Trade Technology Pte. Ltd.

Credit Suisse Holdings

2,500.35
+10.130.41%
Number of Gainers:63
Number of Losers:34
Number of Flat:- -
PE:- -
High:2,507.99
Open:2,490.00
Low:2,489.72
Close:2,490.21
Volume:1.17B
Turnover:249.33B
Market Cap:52.36T
Float Cap:48.98T

Loading ...

Fed's Cook: Inflation Has Been Too High for Too Long, Must Balance Price Stability With Employment

Deep News
·
Oct 01

Kuehne+Nagel Opens Chennai Tech Centre to Expand Digital Logistics Engineering Footprint

Reuters
·
Oct 01

Oil Rises as Supply Concerns Persist Despite Middle East Crude Exports Recovering to Prewar Levels

Dow Jones
·
Oct 01

This Fidelity Manager Likes Coca-Cola, Keurig Dr Pepper, and Other Consumer Staples Bargains

Dow Jones
·
Oct 01

X-Rite Pantone Launches Spectura Portable Sphere Spectrophotometer Platform

Reuters
·
Oct 01

India's CAFE 3 Norms Favour EV Suppliers, Ease Compliance Burden for OEMs, Say BofA, Nomura

Reuters
·
Oct 01

Citi Raises Bitcoin, Ether Forecasts on Strong Crypto Activity

Reuters
·
Oct 01

Thales - Thales and Google Strengthen Their Partnership to Secure Agent-Based AI

THOMSON REUTERS
·
Oct 01

Tesla New Registrations in Sweden +38.4% Year-on-Year in September, Compiler Mobility Sweden Says

THOMSON REUTERS
·
Oct 01

Nippon Prologis REIT Advances Unit Buybacks Under ¥10 Billion Program

TIPRANKS
·
Oct 01

Piper Sandler Raises Microsoft Price Target to $610, Citing Copilot and E7 as New M365 Monetization Drivers

Deep News
·
Oct 01

Goldman Sachs pushes back second Fed rate hike forecast to December, saying need for further tightening is diminishing

Deep News
·
Oct 01

Barclays (BARC) Gets a Buy from J.P. Morgan

TIPRANKS
·
Oct 01

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01